SG3 Management LLC purchased a new position in shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) in the first quarter, HoldingsChannel.com reports. The fund purchased 1,500 shares of the company’s stock, valued at approximately $128,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Lindbrook Capital LLC purchased a new position in shares of Reata Pharmaceuticals during the 4th quarter valued at approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Reata Pharmaceuticals by 100.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 991 shares of the company’s stock valued at $85,000 after purchasing an additional 496 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in shares of Reata Pharmaceuticals by 125.7% during the 4th quarter. Great West Life Assurance Co. Can now owns 2,031 shares of the company’s stock valued at $110,000 after purchasing an additional 1,131 shares in the last quarter. Silvant Capital Management LLC purchased a new stake in Reata Pharmaceuticals in the 4th quarter worth $140,000. Finally, SG Americas Securities LLC purchased a new stake in Reata Pharmaceuticals in the 4th quarter worth $171,000. 54.45% of the stock is owned by institutional investors.
In other Reata Pharmaceuticals news, insider Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock in a transaction on Monday, April 8th. The shares were sold at an average price of $90.17, for a total transaction of $180,340.00. Following the sale, the insider now owns 4,138 shares of the company’s stock, valued at approximately $373,123.46. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Jason Douglas Wilson sold 5,604 shares of Reata Pharmaceuticals stock in a transaction on Monday, March 18th. The stock was sold at an average price of $94.04, for a total transaction of $527,000.16. Following the sale, the chief financial officer now directly owns 4,000 shares in the company, valued at approximately $376,160. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,604 shares of company stock worth $1,572,660. 31.69% of the stock is currently owned by corporate insiders.
Reata Pharmaceuticals (NASDAQ:RETA) last announced its earnings results on Thursday, May 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.01). The business had revenue of $7.77 million for the quarter, compared to the consensus estimate of $7.92 million. As a group, research analysts anticipate that Reata Pharmaceuticals Inc will post -4.61 earnings per share for the current year.
Several equities research analysts recently commented on RETA shares. Zacks Investment Research lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. ValuEngine raised shares of Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. Cantor Fitzgerald reissued a “buy” rating and issued a $100.00 price target on shares of Reata Pharmaceuticals in a report on Thursday, February 28th. BidaskClub raised shares of Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, March 6th. Finally, Citigroup boosted their price target on shares of Reata Pharmaceuticals from $185.00 to $190.00 and gave the stock a “buy” rating in a report on Friday, May 31st. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $116.17.
COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/4371504/sg3-management-llc-purchases-new-stake-in-reata-pharmaceuticals-inc-nasdaqreta.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Read More: The risks of owning bonds
Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals Inc (NASDAQ:RETA).
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.